Open AccessDistinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer
Author(s) -
Emer O. Hanrahan,
Heather Lin,
Edward S. Kim,
Shaoyu Yan,
D. Z. Du,
Kathryn S. McKee,
Hai T. Tran,
J. Jack Lee,
Anderson J. Ryan,
Peter Langmuir,
Bruce E. Johnson,
John V. Heymach
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2009.22.4279
Subject(s) - vandetanib , medicine , vascular endothelial growth factor , oncology , chemotherapy , epidermal growth factor receptor , cancer research , cancer , endocrinology , pharmacology , receptor , tyrosine kinase , vegf receptors
There is an unmet need for biomarkers for identifying patients likely to benefit from anticancer treatments, selecting dose, and understanding mechanisms of resistance. Plasma vascular endothelial growth factor (VEGF) and soluble VEGF receptor 2 (sVEGFR-2) are known to be modulated by VEGF pathway inhibitors. It is unknown whether chemotherapy or VEGFR inhibitor/chemotherapy combinations induce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could be markers of benefit.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom